Brought to you by 
Dow collaborates on Epicyte's transgenic MAb production
01 Oct 2001
Executive Summary
Epicyte Pharmaceutical (Plantibodies technology for producing monoclonal antibodies in plants such as rice and corn) and Dow Chemical's agrosciences division announced a multi-million dollar program to manufacture large quantities of MAbs in plants.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dow collaborates on Epicyte's transgenic MAb production
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice